Verona Pharma plc
Verona Pharma plc (VRNA) Stock Overview
Explore Verona Pharma plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.9B
P/E Ratio
-54.30
EPS (TTM)
$-2.00
ROE
-0.90%
VRNA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Verona Pharma plc (VRNA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 71.16, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $86.04.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -54.30 and a market capitalization of 8.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
David S. Zaccardelli
209
3 More London Riverside, London
2017